TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·November 2, 2026

Vertex Pharmaceuticals Incorporated (VRTX) gains on earnings misses

Vertex Pharmaceuticals Incorporated (VRTX) gains 0.5% after earnings misses, as investors weigh the latest results against the stock’s modest move higher.

Earnings FlashVRTXHealthcareBiotechnology
By TickerSpark·November 2, 2026·2 min read
Vertex Pharmaceuticals Incorporated (VRTX) gains on earnings misses
▌Key Takeaway
Vertex Pharmaceuticals Incorporated (VRTX) reported mixed quarterly results, missing EPS at $4.76 versus $4.82 expected while beating revenue at $3.44 billion versus $3.42 billion. Shares rose 0.51% in after-hours trading, suggesting investors are giving more weight to the revenue beat than the modest earnings miss. For investors, the key question is whether Vertex can convert strong sales into better per-share profit growth going forward.

Vertex Pharmaceuticals Incorporated (VRTX) Earnings Miss, Stock Gains

Vertex Pharmaceuticals Incorporated (VRTX) missed quarterly EPS estimates at $4.76 versus $4.82, but beat revenue estimates at $3.44B versus $3.42B, sending shares up 0.51% to $561.75 in after-hours trading.

Key Numbers

  • EPS: $4.76 actual versus $4.82 estimated, a miss.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $3.44B actual versus $3.42B estimated, a beat.
  • After-hours price: $561.75, up 0.51% from the $558.88 regular-session close.
  • Session volume: 3,046,793 shares versus an average of 1,196,228.
  • Regular-session range: $544.09 to $568.67.
  • Revenue Beat Fails to Produce an Earnings Beat

    The split result gives Vertex a mixed quarter. Revenue cleared estimates, but EPS did not. That means top-line execution did not fully carry through to per-share earnings. The initial 0.51% after-hours gain shows the revenue beat is outweighing the EPS miss for now.

    On the earnings call, management's explanation of the $4.76 EPS result versus the $4.82 estimate will matter. Investors also need the business context behind $3.44B in revenue against the $3.42B estimate. That detail will help separate durable sales strength from a one-quarter earnings shortfall.

    VRTX's recent EPS record is mixed. The company beat estimates in May 2026 and November 2025, but missed in February 2026, August 2026, and this report. The current result therefore does not establish a clean upward earnings trend, even with the revenue beat.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    VRTX delivered a revenue beat and an after-hours gain, but the EPS miss keeps earnings conversion at the center of the investment story.

    Read the full VRTX research report
    ▌Common Questions

    Frequently asked questions

    +Did Vertex Pharmaceuticals beat earnings this quarter?
    No. Vertex Pharmaceuticals Incorporated (VRTX) reported EPS of $4.76, below the $4.82 estimate. Revenue did beat expectations at $3.44 billion versus $3.42 billion.
    +Why did VRTX stock rise after missing EPS?
    VRTX shares rose 0.51% after hours because the company beat revenue estimates, which investors viewed as more important than the small EPS miss. The stock closed the regular session at $558.88 and traded at $561.75 after hours.
    +What were Vertex's key earnings numbers?
    Vertex reported adjusted EPS of $4.76 versus $4.82 expected and revenue of $3.44 billion versus $3.42 billion expected. After-hours volume was 3,046,793 shares, above the average daily volume of 1,196,228.
    +What does Vertex's mixed quarter mean for investors?
    The quarter shows solid top-line performance, but earnings conversion remains uneven. Investors will want management's explanation for the EPS miss and whether revenue strength can translate into more consistent profit growth.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on VRTX?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the VRTX report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full VRTX research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the VRTX report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on VRTX

    More to read

    All articles
    Vertex Pharmaceuticals (VRTX): CF Cash Engine Funds New Growth
    VRTX

    Vertex Pharmaceuticals (VRTX): CF Cash Engine Funds New Growth

    Vertex is using its dominant cystic fibrosis franchise to fund expansion into gene editing, pain, and endocrinology. The stock looks fairly valued near consensus, making execution on ALYFTREK and new launches the key debate.

    Nov 3·21 min
    Vertex Pharmaceuticals Incorporated (VRTX) slips: deep earnings analys
    VRTX

    Vertex Pharmaceuticals Incorporated (VRTX) slips: deep earnings analys

    Vertex Pharmaceuticals Incorporated (VRTX) slips after a mixed quarter, but the deeper read shows revenue beat, a modest EPS miss, and strong cystic fibrosis momentum. This analysis breaks down ALYFTREK growth, pipeline traction, updated guidance, and what the earnings details may mean for the stock.

    Nov 3·6 min